COIL.LSE Coiled Therapeutics plc

Healthcare Biotechnology London Exchange
0.0690 GBX
Close of Nov 3, 2026
6.00 30.00
Market cap
GBX 29.4M
P/E
-
P/B
0.60x
ROE
-138.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is COIL.LSE undervalued?

Graham number

The Graham number of Coiled Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Coiled Therapeutics plc fundamental analysis

No fundamental analysis for Coiled Therapeutics plc yet.

Coiled Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Coiled Therapeutics plc

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, a…

Full company profile